Adarza to commercialize diagnostic assays in 2019

Adarza, a Serra Capital II portfolio company, is set to start selling its diagnostic assays next year. Adarza BioSystems, Inc. is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.

Adarza said its first products will be assays for detecting inflammation, cardiovascular disease and cancer. It expects the first customers to be university researchers and drug-development companies.